Care Delivery

Is Value-Based Pricing the Solution to Controlling the Cost of Oncology Drugs?

Meg Barbor, MPH

February 2017, Vol 7, No 2 - Care Delivery

Anticancer drugs should be priced based on the value they deliver to patients, according to Peter B. Bach, MD, Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center, New York. “The prices have gotten to a scale that they’re actually harming the people the products are intended to help,” Dr Bach said at the 2016 Annual meeting of the Hematology/Oncology Pharmacy Association Oncology Pharmacy Practice Management Program. [ Read More ]

New Prior Authorization Tool Reduces Chemotherapy Costs and Number of Denials

Laura Morgan

February 2017, Vol 7, No 2 - Care Delivery

Prior authorization adds an administrative burden for provider practices and can delay the initiation of therapy to patients. The process can involve lengthy telephone conversations with insurance companies and nontransparent rules, often leaving physicians in the dark as to which therapies will or will not be covered, which can result in high denial rates. [ Read More ]